SCHEMBL20049320

SCHEMBL20049320

CCc1cnc2cc(C(C)C)ccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.43
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SCN4A P35499 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
OGA O60502 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
HIF1A Q16665 1/20 0.35
TYR P14679 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.33
RXRA P19793 1/20 0.32
GRIN1 Q05586 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30134126 0.81 CYP1A2 (0.39) PDE10AOGACYP1A2CYP2C9HIF1A
SCHEMBL14084761 0.77 PDE10A (0.42) PDE10ANPC1RAB9ASCN4ASMN1; SMN2
SCHEMBL10272989 0.77 NQO2 (0.47) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL682228 0.77 NPC1 (0.49) NPC1RAB9ASCN4ASMN1; SMN2HIF1A
SCHEMBL13677497 0.77 NPC1 (0.41) PDE10ANPC1RAB9ASCN4ASMN1; SMN2
SCHEMBL20049295 0.77 NPC1 (0.41) PDE10ANPC1RAB9ASCN4ASMN1; SMN2
SCHEMBL18948584 0.76 PDE10A (0.53) PDE10ANPC1RAB9ASCN4ASMN1; SMN2
SCHEMBL13226945 0.76 PABPC1 (0.41) PDE10ACYP1A2CYP2C9HIF1AKMT2A
SCHEMBL10271340 0.76 HRH4 (0.51) PDE10ACYP1A2KMT2AMEN1MAPT
SCHEMBL12938128 0.73 NPC1 (0.50) NPC1RAB9ASCN4ASMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018067704-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-04-12 WO disclosed